(Q38396605)

2 September 2017

0 references

Gene polymorphism of cytochrome P450 2C19*2 and clopidogrel resistance reflected by platelet function assays: a meta-analysis (English)

1 reference

2 September 2017

1 reference

Xiaowen Hou

1

1 reference

2 September 2017

Jingpu Shi

series ordinal

2

1 reference

2 September 2017

Hao Sun

series ordinal

3

1 reference

2 September 2017

publication date

5 July 2014

1 reference

European Journal of Clinical Pharmacology

2 September 2017

published in

1 reference

2 September 2017

volume

70

1 reference

2 September 2017

issue

9

1 reference

2 September 2017

page(s)

1041-1047

1 reference

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1714-X

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1714-X

Adenosine diphosphate as a mediator of platelet aggregation in vivo: an editorial view.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1714-X

P2Y12, a new platelet ADP receptor, target of clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1714-X

Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1714-X

Clinical, pharmacokinetic, and pharmacogenetic determinants of clopidogrel resistance in Korean patients with acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1714-X

Clopidogrel resistance: myth or reality?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1714-X

CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1714-X

Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1714-X

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1714-X

Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1714-X

Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1714-X

Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1714-X

Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1714-X

Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1714-X

Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1714-X

Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1714-X

Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1714-X

Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1714-X

Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1714-X

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1714-X

Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1714-X

Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1714-X

Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1714-X

Usefulness of high clopidogrel maintenance dose according to CYP2C19 genotypes in clopidogrel low responders undergoing coronary stenting for non ST elevation acute coronary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1714-X

The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1714-X

Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1714-X

Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1714-X

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1714-X

Individual variations of platelet inhibition after loading doses of clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1714-X

Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1714-X

Clopidogrel "resistance": where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1714-X

Clopidogrel: a pharmacogenomic perspective on its use in coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1714-X

Pharmacokinetic profile of 14C-labeled clopidogrel

21 January 2018

1 reference

12 December 2020

Impact of CYP2C19 polymorphism and smoking on response to clopidogrel in patients with stable coronary artery disease.

1 reference

12 December 2020

Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement

1 reference

12 December 2020

Identification and biological activity of the active metabolite of clopidogrel

1 reference

12 December 2020

Clopidogrel resistance caused by a failure to metabolize clopidogrel into its metabolites

1 reference

12 December 2020

Relationships of blood stasis syndrome, CYP2C19 gene polymorphism with clopidogrel resistance and post-PCI prognosis

1 reference

12 December 2020

Cytochrome P450 3A4*22, PPAR-α, and ARNT polymorphisms and clopidogrel response

1 reference

12 December 2020

Association of CYP2C19 genotype with periprocedural myocardial infarction after uneventful stent implantation in Chinese patients receiving clopidogrel pretreatment

1 reference

12 December 2020

10.1007/S00228-014-1714-X

Identifiers

DOI

1 reference

Dimensions Publication ID

2 September 2017

1011787834

0 references

Fatcat ID

release_dx2p6mvmijadbpawm4wu7vugda

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/dx2p6mvmijadbpawm4wu7vugda

24 November 2022

mapped directly with Wikidata item

1 reference